Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vivet raises €37.5m to advance gene therapies for metabolic diseases
Vivet Therapeutics, which is focused on developing novel gene therapies for rare, inherited metabolic diseases, has raised €37.5m in a Series A financing round.
Drug Discovery
-
05 May 2017
-
05 May 2017
Poxel’s diabetes drug Imeglimin succeeds in phase 2b study in Japan
Poxel has announced positive top line results of a Phase 2b trial of Imeglimin for type 2 diabetes treatment in Japan.
-
04 May 2017
Sosei to invest in UK biopharmaceutical firm MiNA Therapeutics
Sosei has agreed to make an investment in and acquire an exclusive option to potentially acquire MiNA Therapeutics, a private UK biopharmaceutical company.
-
04 May 2017
AstraZeneca, Pieris form $2.1bn respiratory drug collaboration
AstraZeneca will develop new inhaled respiratory treatments based on Pieris Pharmaceuticals’ Anticalin platform through a collaboration that could generate more than $2bn for the US firm.
-
02 May 2017
Shire licenses dry-eye treatment from Parion Sciences
Shire has secured exclusive global rights to develop Parion Sciences' Phase II-stage epithelial sodium channel (ENaC) inhibitor P-321 for the potential treatment of dry eye.
-
28 Apr 2017
Takeda, Harrington to advance development of rare disease therapeutics
Takeda Pharmaceutical has entered into a multi-year partnership with Harrington Discovery Institute at University Hospitals in Cleveland, Ohio to advance the development of rare disease rherapeutics.
-
27 Apr 2017
Gates Foundation leads $45.5m round for biotechnology firm Arsanis
Clinical-stage biopharmaceutical firm Arsanis has secured $45.5m in a Series D financing round led by the Bill & Melinda Gates Foundation.
-
21 Apr 2017
Immune Pharmaceuticals licenses cancer treatment’s Latin America rights to Pint
Immune Pharmaceuticals has entered into a letter of intent with Pint Pharma regarding license and commercializion of Ceplene in Latin America.
-
20 Apr 2017
Alpine Immune Sciences to merge with Nivalis Therapeutics
Alpine Immune Sciences has agreed to merge with a subsidiary of Nivalis Therapeutics in an all-stock transaction.
-
17 Apr 2017
Lyndra secures $23m funding to develop therapeutic oral delivery platform
Lyndra has secured $23m Series A financing, led by Polaris Partners, with participation from Quark Venture and GF Securities, Yonghua Capital, Healthlink Capital, Suffolk Equity, Partners Healthcare among others.